INOCA Spanish National Registry

NCT06327672 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-03-28

No results posted yet for this study

Summary

Coronary atherosclerosis is the most common cause of ischaemic heart disease. About 40-50% of patients with symptoms and documented ischaemia on non-invasive tests do not show obstructive coronary artery disease on coronary angiography. This cause of ischaemic heart disease called INOCA (Ischemic Non-Obstructive Coronary Artery), far from having a benign prognosis, is associated with an increase in major adverse cardiac events (MACE) as well as increased functional limitation. The current European Society of Cardiology clinical practice guidelines for the management of chronic coronary syndrome establish for the first time a IIa recommendation for the invasive analysis of coronary flow reserve (CFR) and microvascular resistance index (MRI) in symptomatic patients with INOCA. The acetylcholine (Ach) test, based on intracoronary (ic) administration, is established as indication IIb for the assessment of micro or macrovascular vasospasm in patients with suspected vasospastic angina (VSA) (4). A national multicentre registry would allow us to determine the prevalence of INOCA and its different endotypes in our setting.

Conditions

  • Non-Obstructive Coronary Atherosclerosis
  • Ischemia
  • Coronary Disease

Sponsors & Collaborators

  • Hospital San Carlos, Madrid

    collaborator OTHER
  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

    collaborator OTHER
  • Hospital Universitario Virgen de la Arrixaca

    collaborator OTHER
  • University Hospital Gregorio Marañón

    collaborator OTHER
  • Hospital Clínico Universitario de Valladolid

    collaborator OTHER
  • Hospital Universitario Puerta del Mar

    collaborator OTHER
  • Hospital Universitari de Bellvitge

    collaborator OTHER
  • Hospital Universitario La Fe

    collaborator OTHER
  • Hospital Clínico Universitario de Valencia

    collaborator OTHER
  • Hospital Universitario La Paz

    collaborator OTHER
  • Hospital General Universitario de Alicante

    collaborator OTHER
  • Complejo Hospitalario Universitario de Huelva

    collaborator OTHER
  • Hospital General Universitario de Castellón

    collaborator OTHER
  • Hospital de Manises

    collaborator OTHER
  • Hospital Clinic of Barcelona

    collaborator OTHER
  • Hospital Miguel Servet

    collaborator OTHER
  • Hospital Clínico Universitario Lozano Blesa

    collaborator OTHER
  • Hospital Donostia

    collaborator OTHER
  • Hospital General Universitario Elche

    collaborator OTHER
  • Hospital Universitario Virgen del Rocio

    collaborator UNKNOWN
  • Hospital de la Ribera

    collaborator OTHER
  • Hospital de la Santa creu i Sant Pau - Barcelona

    collaborator OTHER
  • Hospital Virgen de la Salud

    collaborator OTHER
  • Hospital Universitario San Juan de Alicante

    collaborator OTHER
  • Hospital Universitario de Torrevieja

    collaborator UNKNOWN
  • University Hospital of the Nuestra Señora de Candelaria

    collaborator OTHER
  • Hospital de Basurto

    collaborator OTHER
  • Hospital Universitario Ramon y Cajal

    collaborator OTHER
  • Hospital Universitario Fundación Jiménez Díaz

    collaborator OTHER
  • Puerta de Hierro University Hospital

    collaborator OTHER
  • Hospital Universitario 12 de Octubre

    collaborator OTHER
  • University of Salamanca

    collaborator OTHER
  • Hospital Universitario Marqués de Valdecilla

    collaborator OTHER
  • Hospital Clinico Universitario de Santiago

    collaborator OTHER
  • Complexo Hospitalario Universitario de A Coruña

    collaborator OTHER
  • Eva Rumiz González

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-24
Primary Completion
2025-03-31
Completion
2026-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06327672 on ClinicalTrials.gov